EP3448391
MEÐFERÐARAÐFERÐIR VIÐ SJÚKDÓMUM ÞAR SEM IL-13-VIRKNI ER SKAÐLEG, MEÐ NOTKUN Á MÓTEFNUM GEGN IL-13
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
27.4.2017EP published:
29.5.2024EP application number:
17790401.8
EP translation filed:
24.6.2024Grant published:
15.7.2024EPO information:
European Patent Register
Max expiry date:
26.4.2037Expiry date:
26.4.2026Next due date:
30.4.2026
Title in English:
METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIESLanguage of the patent:
English
Timeline
Today
27.4.2017EP application
29.5.2024EP Publication
24.6.2024Translation submitted
15.7.2024Registration published
26.4.2026Expires
Owner
Name:
AbbVie Manufacturing Management Unlimited CompanyAddress:
70 Sir John Rogerson's Quay, Dublin, 2, IE
Inventor
Name:
TIMONY, GreggAddress:
Carlsbad, CA 92009, US
Name:
GUJRATHI, SheilaAddress:
Rancho Santa Fe, CA 92067, US
Name:
PEACH, RobertAddress:
San Diego, CA 92103, US
Name:
OLSON, AllanAddress:
San Diego, CA 92121, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201662328539 PDate:
27.4.2016Country:
US
Classification
Categories:
A61K 31/56, A61K 39/395, A61K 45/06, C07K 16/24
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 18.3.2025
Expires: 26.4.2026
Payer: Árnason Faktor ehf.